A Systematic Review on the Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in Gastrointestinal Motility Disorders: More Control, Less Risk.
gastrointestinal motility disorders
gut-brain axis
irritable bowel syndrome
serotonin
ssri
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
16
06
2022
accepted:
04
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Gastrointestinal motility disorders have been thought to occur due to an imbalance in the interaction of the gut-brain axis, which is regulated by serotonin. This recent discovery can be exploited to find newer therapeutic agents such as selective serotonin reuptake inhibitors for functional gastrointestinal disorders. PubMed, PubMed Central (PMC), and Medline databases were used to obtain the data. Meta-analyses, systematic reviews, randomized control trials, and reviews were included and analyzed in the data. Of the 19240 studies, 23 were extracted, and after appropriate quality assessment, they were utilized in this systematic review. They included two meta-analyses, four systematic reviews, two randomized control trials, and 15 review articles. The systematic review focuses on the efficacy of selective serotonin reuptake inhibitors (SSRIs) as compared to other treatment modalities for disorders of gut-brain interaction. It explores various studies analyzing SSRIs for their mechanism of action, their desirable effects for treating irritable bowel syndrome, and their tolerability in patients. SSRIs are effective and safe in treating overall symptoms of gastrointestinal motility disorders, particularly constipation-predominant disorders. They seem to have a better side effect profile than other drugs. This should encourage physicians to prescribe SSRIs early on in the disease.
Identifiants
pubmed: 36081982
doi: 10.7759/cureus.27691
pmc: PMC9440984
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e27691Informations de copyright
Copyright © 2022, Acharekar et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Rev Gastroenterol Hepatol. 2013 Aug;10(8):473-86
pubmed: 23797870
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Curr Gastroenterol Rep. 2018 Nov 5;20(12):58
pubmed: 30397821
Molecules. 2022 Mar 03;27(5):
pubmed: 35268781
Medicine (Baltimore). 2019 Aug;98(32):e15920
pubmed: 31393342
World J Gastroenterol. 2014 Jul 21;20(27):8796-806
pubmed: 25083054
Lancet Gastroenterol Hepatol. 2020 Feb;5(2):117-131
pubmed: 31859183
J Transl Med. 2022 Apr 11;20(1):173
pubmed: 35410233
Dig Dis. 2020;38(2):122-127
pubmed: 31851972
Int J Mol Sci. 2021 Sep 23;22(19):
pubmed: 34638577
Panminerva Med. 2018 Dec;60(4):213-222
pubmed: 30257542
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Mar;162(1):1-9
pubmed: 29358788
World J Gastroenterol. 2014 Jul 21;20(27):8807-20
pubmed: 25083055
Gastroenterology. 2015 Aug;149(2):340-9.e2
pubmed: 25921377
J Pain. 2018 Jul;19(7):717-726
pubmed: 29412183
J Psychosom Res. 2021 Feb;141:110351
pubmed: 33412422
Wien Med Wochenschr. 2018 Mar;168(3-4):62-66
pubmed: 28887729
J Cell Physiol. 2017 Sep;232(9):2359-2372
pubmed: 27512962
Arq Gastroenterol. 2021 Jan-Mar;58(1):120-126
pubmed: 33909790
Nutrients. 2021 Aug 31;13(9):
pubmed: 34578939
Am J Gastroenterol. 2019 Jan;114(1):21-39
pubmed: 30177784
PLoS One. 2015 Aug 07;10(8):e0127815
pubmed: 26252008
World J Gastroenterol. 2014 Jun 14;20(22):6759-73
pubmed: 24944467
Mayo Clin Proc. 2018 Dec;93(12):1858-1872
pubmed: 30522596